Company / EPS (Diluted)
Vistagen Therapeutics, Inc. EPS (Diluted) History
FY2011-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.50
FY2021
5-year range
-$29.08 / -$0.50
FY2017-FY2021
Trend
+67.5%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $-29.08 to $-0.50 over the past 4 years.
Based on SEC 10-K filings.
-0.50 in FY2021.
Improved from $-29.08 to $-0.50 over the past 4 years.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, eps (diluted) increased 67.5% year-over-year.
- Lowest eps (diluted) in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -$0.50 | +67.5% |
| FY2018 | -$1.54 | +94.7% |
| FY2017 | -$29.08 | -2189.8% |
| FY2014 | -$1.27 | -53.0% |
| FY2012 | -$0.83 | +54.1% |
| FY2011 | -$1.81 | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026